InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,487.03
(
0.00%
)
US TECH 100
19,470.80
(
0.32%
)
Dow Jones
38,834.86
(
0.00%
)
Brent Oil
84.99
(
0.34%
)
Bitcoin
65,961.38
(
1.53%
)
Post# of 252256
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 834
Posts 119875
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: vinmantoo post# 142378

Tuesday, 05/22/2012 7:13:20 PM

Tuesday, May 22, 2012 7:13:20 PM

Post# of 252256

ONXX—One might think that using KRAS patients makes sense given the MOA of Nexavar. Was the omission likely due to the small numbers of such patients alive after two or more treatment?

I’m not sure. One possible reason is that the relevance of KRAS in NSCLC was less established when this study was designed, which was in 2008. (The study began enrolling patients in early 2009.)

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up